Table 1 Clinicalpathologic features between study groups
Variables | GS ≤ 6 | GS ≥ 7 | P Value |
|---|---|---|---|
N = 61 | N = 100 | ||
Age (IQR), years | 65(57, 72) | 65(61, 70) | 0.514 |
tPSA (IQR), ng/ml | 10.00(6.81, 13.54) | 15.10(9.81, 20.70) | <0.001 |
Prostate volume (IQR),ml | 38.69(35.41, 42.44) | 38.31(34.81, 43.54) | 0.989 |
Neutrophil count (IQR), 109/L | 3.30(2.89, 4.00) | 3.59(2.86, 4.74) | 0.201 |
Lymphocyte count (IQR), 109/L | 1.96(1.57, 2.34) | 2.06(1.65, 2.47) | 0.370 |
NLR (IQR), % | 1.68(1.32, 2.07) | 1.96(1.43, 2.49) | 0.008 |
BMI (Mean ± SD), kg/m2 | 25.66 ± 2.57 | 25.19 ± 2.96 | 0.631 |
Smoking History, No.(%) | |||
No | 48(78.9%) | 66(66.0%) | 0.086 |
Yes | 13(21.3%) | 34(34.0%) | |
Alcohol History, No.(%) | |||
No | 42(68.3%) | 60(60.0%) | 0.258 |
Yes | 19(31.7%) | 40(40.0%) | |
Positive cores(IQR), No. | 6(5, 8) | 6(4, 8) | 0.570 |
Max cancer of core(IQR), % | 50(30, 65) | 50(30, 60) | 0.489 |
Pathologic T Stage, No.(%) | |||
pT2 | 50(82.0%) | 73(73.0%) | 0.194 |
pT3 | 11(18.0%) | 27(27.0%) | |
Pathologic N Stage, No.(%) | |||
pN0 | 53(86.9%) | 81(81.0%) | 0.332 |
pN1 | 8(13.1%) | 19(19.0%) | |